The global Continuous Glucose Monitoring Market (CGM) was valued at US$ 2,035.8 million in 2015 and is projected to reach US$ 14,414.1 million by 2024, according to a new report by published by Coherent Market Insights. CGM devices allow monitoring of glucose level during bedtime, noon, pre/post lunch, or before/after exercise, which is a major factor propelling growth of the continuous glucose monitoring market.
The global CGM market is undergoing a major technological change that is resulting in a major paradigm shift. Novel devices such as Eversense CGM and GlySens ICGM, which can be implanted for relatively long duration of time, are expected to experience major growth traction, while demand for conventional CGM systems is expected to decrease in the near future. Demand would be largely driven by increasing awareness among the diabetic patients, especially in emerging markets such as Brazil, India, Indonesia, China, Russia, and South Africa regarding the various benefits of using these systems in order to maintain a healthy life. Renewed and dedicated effort from manufacturers and governments across these countries is essential to increase patient awareness and educate them about the importance of regular glucose monitoring in order to keep a check on diabetes and related diseases.
To know the latest trends and insights prevalent in this market, click the link below:
Continuous monitoring glucose devices have witnessed increased demand from critical care patients, in order to avoid complexities in health condition. As a result, the device has witnessed high adoption in ICU units, besides home care and clinic settings. However, calibration issues is one of the prominent factor inhibiting market growth.
Technology collaboration helps companies leverage technical expertise of the other party and is a key trend prevalent in this industry. For instance, Medtronic collaborated with Fitbit, Inc. to integrate the physical activity data of the person with glucose levels into its iPro2 myLog application. Similarly, Senseonics, Inc. launched Eversense, the world’s first long-term implantable CGM, in January 2016. The evolving technological trend is transforming the method of monitoring glucose in the body.
However, therapeutic decisions as an outcome of measurement from tissue (interstitial fluid) lacks accuracy. Therefore, market is witnessing increasing adoption of CGM devices to be used in conjunction with conventional blood glucose monitoring devices, as a tool for diabetes management rather than as a replacement for the same. Companies therefore, need to work on the mechanism of the CGM system to make it more reliable in terms of diagnosis of diabetes, rather than just a tool for management.
Key takeaways of the market:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Email: [email protected]
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.